Juan Martínez-Barea

  • Current company Universal DX
  • Location Spain
  • Industry Healthcare

Early detection is one of the most powerful weapons we have in the battle against cancer. While traditional options are expensive, ineffective, and have low compliance rates, UDX is creating a cancer platform consisting of minimally invasive, blood-based solutions for early cancer detection. As colorectal cancer (CRC) is the third most deadly cancer worldwide, the founders decided that CRC early detection would be their starting point. With $44M in funding from top tech entrepreneurs, family offices, and biotech funds and 2 approved and 6 filed patents, Universal DX is poised to tackle the $20B CRC screening test market before expanding to a broader panel of cancers on its mission to win the fight against cancer.

Stay up to date on our entrepreneurs, events, research and more.